Nektar Therapeutics(NKTR)

Biotechnology company.

3 Insights

Investment Insights

AI-generated insights about Nektar Therapeutics from various financial sources

Tuesday, September 23, 2025

Bullish

The speaker is long the stock but only in a 'very small amount,' indicating it's a speculative position with mild bullish conviction.

Thursday, June 26, 2025

Neutral

Mentioned as a neutral example of a company with a poor management track record that recently had a positive outcome, serving as a potential parallel for INMB's situation.

Martin Shkreli
6/26/25 -35%
Martin ShkreliYouTube296 days ago

Monday, June 23, 2025

Bullish
Target: 10x return

Viewed as a high-risk, high-reward speculation trading below its cash value. The speaker notes the asymmetric risk/reward (potential 10x return vs. 30% decline) makes it a tempting short-term trade ahead of data results, despite a history of failures.

Martin Shkreli
6/23/25 -29%
Martin ShkreliYouTube296 days ago